Shares of Lantheus Holdings Inc (NASDAQ:LNTH) have been assigned a consensus rating of “Buy” from the seven analysts that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $24.00.

LNTH has been the topic of several analyst reports. Jefferies Group lifted their target price on shares of Lantheus from $22.00 to $27.00 and gave the company a “buy” rating in a report on Friday, November 3rd. Wells Fargo & Co raised shares of Lantheus from a “market perform” rating to an “outperform” rating in a report on Thursday, November 2nd. Zacks Investment Research raised shares of Lantheus from a “hold” rating to a “strong-buy” rating and set a $26.00 target price on the stock in a report on Tuesday, November 7th. BidaskClub raised shares of Lantheus from a “hold” rating to a “buy” rating in a report on Wednesday, December 27th. Finally, Credit Suisse Group lifted their target price on shares of Lantheus from $19.00 to $23.00 and gave the company a “neutral” rating in a report on Friday, November 3rd.

In other news, CFO John W. Crowley sold 3,866 shares of Lantheus stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $23.52, for a total value of $90,928.32. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Michael P. Duffy sold 11,917 shares of Lantheus stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $21.63, for a total transaction of $257,764.71. Following the completion of the sale, the insider now directly owns 152,301 shares in the company, valued at approximately $3,294,270.63. The disclosure for this sale can be found here. In the last ninety days, insiders sold 48,752 shares of company stock worth $1,077,129. Insiders own 2.30% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in shares of Lantheus by 87.5% in the second quarter. Vanguard Group Inc. now owns 1,478,350 shares of the medical equipment provider’s stock valued at $26,093,000 after purchasing an additional 689,954 shares during the period. LSV Asset Management lifted its stake in shares of Lantheus by 57.5% in the fourth quarter. LSV Asset Management now owns 953,906 shares of the medical equipment provider’s stock valued at $19,507,000 after purchasing an additional 348,298 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Lantheus by 73.7% in the third quarter. Dimensional Fund Advisors LP now owns 911,311 shares of the medical equipment provider’s stock valued at $16,221,000 after purchasing an additional 386,771 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Lantheus by 12.6% in the second quarter. Renaissance Technologies LLC now owns 691,000 shares of the medical equipment provider’s stock valued at $12,196,000 after purchasing an additional 77,200 shares during the period. Finally, JPMorgan Chase & Co. lifted its stake in shares of Lantheus by 60.7% in the third quarter. JPMorgan Chase & Co. now owns 690,419 shares of the medical equipment provider’s stock valued at $12,220,000 after purchasing an additional 260,901 shares during the period. Hedge funds and other institutional investors own 91.07% of the company’s stock.

Lantheus (LNTH) opened at $20.15 on Thursday. Lantheus has a 52-week low of $8.85 and a 52-week high of $24.45. The company has a debt-to-equity ratio of -3.41, a quick ratio of 2.46 and a current ratio of 2.96. The stock has a market cap of $755.75 and a price-to-earnings ratio of 25.19.

WARNING: “Lantheus Holdings Inc (LNTH) Receives Average Rating of “Buy” from Analysts” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2018/02/08/lantheus-holdings-inc-lnth-receives-average-rating-of-buy-from-analysts.html.

Lantheus Company Profile

Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.